---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-009967"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T12:39:26.774718+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharma Q4 revenue +11.6% to $10.4M; full-year net loss $6.4M

## Summary
- Q4 2024 net revenue $10.4M, up 11.6% YoY; full-year revenue $38M.
- Full-year net loss $6.4M; adjusted loss $1.0M (excl. $1.3M product acquisition costs).
- Cash $18M, total assets $76M, liabilities $53M, shareholders' equity $23M at year-end.
- Phase 2 ifetroban DMD study positive top-line; Vibativ approved in China.
- Kristalose $15.3M, Sancuso $9M, Vibativ $7.2M, Caldolor $5M in 2024 revenue.

## SEC filing metadata
- accession: 0001628280-25-009967
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828025009967/0001628280-25-009967-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828025009967/cpix-20250304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-009967
- JSON: https://secwatch.observer/filing/0001628280-25-009967.json
- Plain text: https://secwatch.observer/filing/0001628280-25-009967.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.